Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/20941
Full metadata record
DC FieldValueLanguage
dc.contributor.authorManoussakis, M. N.en
dc.contributor.authorGermanidis, G. S.en
dc.contributor.authorDrosos, A. A.en
dc.contributor.authorMoutsopoulos, H. M.en
dc.date.accessioned2015-11-24T19:11:34Z-
dc.date.available2015-11-24T19:11:34Z-
dc.identifier.issn0961-2033-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20941-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectArthritis, Rheumatoid/blood/*immunology/urineen
dc.subjectEnzyme-Linked Immunosorbent Assayen
dc.subjectFemaleen
dc.subjectHot Temperatureen
dc.subjectHumansen
dc.subjectLupus Erythematosus, Systemic/blood/*immunology/urineen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectReceptors, Interleukin-2/*metabolismen
dc.subjectSolubilityen
dc.titleImpaired urinary excretion of soluble IL-2 receptors in patients with systemic lupus erythematosus and rheumatoid arthritisen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/1301961-
heal.identifier.secondaryhttp://lup.sagepub.com/content/1/2/105-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1992-
heal.abstractSeveral previous studies have demonstrated increased in vivo release of soluble interleukin-2 receptors (sIL-2R) in patients with disorders associated with cellular activation. In this study attempting to understand better the role of sIL-2R released in vivo, we investigated the sIL-2R levels in paired serum and urine samples from 25 patients with systemic lupus erythematosus (SLE), 41 patients with rheumatoid arthritis (RA) and 20 healthy subjects. Using an ELISA for sIL-2R, we detected significantly increased urinary sIL-2R levels in normal individuals (868 +/- 114 units/ml) compared to the corresponding serum samples (209 +/- 25, P < 0.001, mean urine/serum sIL-2R ratio: 4.5 +/- 0.6), which suggests that the clearance of sIL-2R from circulation is largely kidney-dependent. The patients with SLE and RA exhibited significantly increased serum sIL-2R levels compared to normals (682 +/- 115 and 734 +/- 101 units/ml, respectively, P < 0.001) and these levels correlated with disease activity. However, urinary excretion of sIL-2R in these patients (SLE: 620 +/- 154 units/ml; RA: 1084 +/- 148 units/ml) was found to be significantly decreased (mean urine/serum sIL-2R ratio in SLE: 0.9 +/- 0.2; in RA: 1.9 +/- 0.2; P < 0.001) compared to normals, possibly contributing to the accumulation of these soluble receptors in the serum of autoimmune patients after their release from cells. Our findings can be attributed either to the binding of the sIL-2R to serum protein(s) or to distinct structural features of serum sIL-2R in SLE and RA patients, interfering with the urinary excretion of these molecules.en
heal.journalNameLupusen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons